Page 3 - Pipeline Overview News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pipeline overview. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pipeline Overview Today - Breaking & Trending Today

Axsome Therapeutics (NASDAQ:AXSM) Trading Up 4%

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating)’s share price was up 4% during mid-day trading on Wednesday . The stock traded as high as $72.47 and last traded at $72.24. Approximately 294,226 shares changed hands during trading, a decline of 67% from the average daily volume of 884,269 shares. The stock had previously closed at […] ....

United States , Boxer Capital , Morgan Stanley , Vr Adviser , Axsome Therapeutics Inc , Axsome Therapeutics , Get Rating , Products Overview , Pipeline Overview , Axsome Therapeutics Daily , Nasdaq Axsm ,

Axsome Therapeutics, Inc. to Post Q2 2023 Earnings of ($1.32) Per Share, Zacks Research Forecasts (NASDAQ:AXSM)

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) – Analysts at Zacks Research cut their Q2 2023 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a research note issued on Monday, May 22nd. Zacks Research analyst K. Shah now expects that the company will post earnings of ($1.32) per share for the quarter, […] ....

United States , Capital Management , Pricet Rowe Associates Inc , Zacks Research , Morgan Stanley , Axsome Therapeutics Inc , Victory Capital Management Inc , China Universal Asset Management Co , Group Plc , Analysts At Zacks Research , Axsome Therapeutics , Get Rating , Axsome Therapeutic , Universal Asset Management , General Group Plc , Products Overview , Pipeline Overview , Axsome Therapeutics Daily , Nasdaq Axsm , Earnings Estimates ,

Guggenheim Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $100.00

Axsome Therapeutics (NASDAQ:AXSM – Get Rating) had its price objective upped by Guggenheim from $90.00 to $100.00 in a research report sent to investors on Tuesday morning, The Fly reports. AXSM has been the topic of a number of other research reports. StockNews.com began coverage on Axsome Therapeutics in a research report on Thursday, March […] ....

United States , China Universal Asset Management Co , Axsome Therapeutics Company Profile , Axsome Therapeutics Inc , Tower Research Capital , Armstrong Advisory Group Inc , Morgan Stanley , Axsome Therapeutics , Get Rating , Moderate Buy , Financial Advisors , Advisory Group , Universal Asset Management , Research Capital , Dark Forest Capital Management , Products Overview , Pipeline Overview , Axsome Therapeutics Daily , Nasdaq Axsm , Boost Price Target ,

Axsome Therapeutics, Inc. Forecasted to Earn Q1 2025 Earnings of ($0.34) Per Share (NASDAQ:AXSM)

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) – Equities researchers at William Blair issued their Q1 2025 earnings per share estimates for shares of Axsome Therapeutics in a report released on Tuesday, May 9th. William Blair analyst M. Minter forecasts that the company will post earnings of ($0.34) per share for the quarter. The consensus […] ....

United States , William Blair , Morgan Stanley , Axsome Therapeutics Inc , China Universal Asset Management Co , Armstrong Advisory Group Inc , Tower Research Capital , Axsome Therapeutics Company Profile , Axsome Therapeutics , Get Rating , Axsome Therapeutic , Financial Advisors , Advisory Group , Universal Asset Management , Research Capital , Dark Forest Capital Management , Products Overview , Pipeline Overview , Axsome Therapeutics Daily , Nasdaq Axsm , Earnings Estimates ,

Axsome Therapeutics (NASDAQ:AXSM) Upgraded to Hold at StockNews.com

Axsome Therapeutics (NASDAQ:AXSM – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday. AXSM has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price target on shares of […] ....

United States , Axsome Therapeutics Inc , Tower Research Capital , Quent Capital , Morgan Stanley , China Universal Asset Management Co , Armstrong Advisory Group Inc , Axsome Therapeutics , Get Rating , Financial Advisors , Advisory Group , Universal Asset Management , Research Capital , Products Overview , Pipeline Overview , Axsome Therapeutics Daily , Nasdaq Axsm , Stocknews Com ,